ArticleTropical medicine and health2025
Factors contributing to human and veterinary medicine shortages in developing countries: perspectives of suppliers and regulators in Namibia.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedicine shortages remain a pervasive global public health challenge, particularly affecting import-dependent countries with limited local manufacturing capacity. Namibia's reliance on pharmaceutical imports makes it vulnerable to supply chain disruptions across human and veterinary health sectors.
aimThis study explores availability and factors contributing to medicine shortages in Namibia from the perspectives of regulators and pharmaceutical suppliers.
methodsAn exploratory qualitative study was conducted between August and October 2024. In-depth semi-structured interviews were carried out with 11 key stakeholders in the pharmaceutical sector involved in procurement, distribution, and regulation across public and private sectors, including animal health. Thematic analysis was employed.
resultsFive themes emerged: persistent shortages affecting both sectors with pronounced public sector challenges, particularly for chronic disease treatments (antihypertensives, insulin, anti-tuberculosis medicines, antiretrovirals); general supply chain constraints including limited local manufacturing, small market size, and global active ingredient shortages; public sector barriers including absence of formal procurement contracts and manual systems; regulatory bottlenecks encompassing processing delays and capacity constraints; and veterinary sector vulnerabilities despite economic importance.
conclusionsStakeholders identified medicine shortages as resulting from interconnected systemic challenges encompassing procurement, regulatory, infrastructural, and market-based constraints. Key patterns emerged: Namibia's regional reclassification appears to have increased supply vulnerabilities; absence of formal procurement contracts has led to reliance on emergency mechanisms; and regulatory capacity limitations may compound supply challenges. These interconnected factors suggest the need for coordinated multi-domain interventions, though further research is needed to quantify these relationships. Findings may inform policy considerations for improving medicine security in similar resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.